RecruitingNCT03375619

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Sponsor

Medical College of Wisconsin

Enrollment

500 participants

Start Date

Dec 1, 2017

Study Type

OBSERVATIONAL

Conditions

Diffuse Large B Cell Lymphoma Chronic Lymphocytic Leukemia Multiple Myeloma Mantle Cell Lymphoma Follicular Lymphoma Burkitt Lymphoma Lymphoma, Small Lymphocytic Central Nervous System Lymphoma Lymphomas Non-Hodgkin's B-Cell

Summary

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This trial is a long-term follow-up study that tracks the health outcomes of patients who previously received a cutting-edge immune cell therapy called CAR-T cell therapy — where a patient's own immune cells are engineered to fight cancer — to monitor their long-term safety and well-being over many years. **You may be eligible if...** - You previously participated in a CAR-T cell therapy study at Froedtert Hospital and the Medical College of Wisconsin **You may NOT be eligible if...** - There are no medical exclusion criteria for this study — all prior CAR-T participants at this institution are welcome to enroll Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERLong-Term Follow-Up of Participants who Received CAR-T cells

No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.